These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 12768334

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy.
    Virgolini I, Patri P, Novotny C, Traub T, Leimer M, Füger B, Li SR, Angelberger P, Raderer M, Wogritsch S, Kurtaran A, Kletter K, Dudczak R.
    Ann Oncol; 2001; 12 Suppl 2():S41-5. PubMed ID: 11762351
    [Abstract] [Full Text] [Related]

  • 3. Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours.
    Rodrigues M, Traub-Weidinger T, Li S, Ibi B, Virgolini I.
    Eur J Nucl Med Mol Imaging; 2006 May; 33(5):532-40. PubMed ID: 16491425
    [Abstract] [Full Text] [Related]

  • 4. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET.
    Rodrigues M, Traub-Weidinger T, Leimer M, Li S, Andreae F, Angelberger P, Dudczak R, Virgolini I.
    Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1144-51. PubMed ID: 15909194
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy.
    Virgolini I, Traub T, Leimer M, Novotny C, Pangerl T, Ofluoglu S, Halvadjieva E, Smith-Jones P, Flores J, Li SR, Angelberger P, Havlik E, Andreae F, Raderer M, Kurtaran A, Niederle B, Dudczak R.
    Q J Nucl Med; 2000 Mar; 44(1):50-8. PubMed ID: 10932601
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of (11)C-acetate positron emission tomography and (67)Gallium citrate scintigraphy in patients with hepatocellular carcinoma.
    Li S, Beheshti M, Peck-Radosavljevic M, Oezer S, Grumbeck E, Schmid M, Hamilton G, Kapiotis S, Dudczak R, Kletter K.
    Liver Int; 2006 Oct; 26(8):920-7. PubMed ID: 16953831
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.
    Virgolini I, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E, Vorbeck F, Bischof C, Leimer M, Dorner G, Kletter K, Niederle B, Scheithauer W, Smith-Jones P.
    J Nucl Med; 1998 Nov; 39(11):1928-36. PubMed ID: 9829585
    [Abstract] [Full Text] [Related]

  • 19. A comparison of 111In-octreotide and 67Ga scintigraphy in malignant lymphoma.
    Cerulus G, Léonard JP.
    Nucl Med Commun; 1997 Jul; 18(7):616-22. PubMed ID: 9342098
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.